menu search

RETA / Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate

Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same. Read More
Posted: Apr 4 2022, 11:18
Author Name: Zacks Investment Research
Views: 103114

RETA News  

CPMG Inc Acquires Significant Stake in Reata Pharmaceuticals Inc

By GuruFocus
August 1, 2023

CPMG Inc Acquires Significant Stake in Reata Pharmaceuticals Inc

CPMG Inc (Trades, Portfolio), a prominent investment firm, recently expanded its portfolio with the acquisition of a substantial number of shares in R more_horizontal

Reata Pharmaceuticals stock opened 50% up on Friday: what happened?

By Invezz
July 28, 2023

Reata Pharmaceuticals stock opened 50% up on Friday: what happened?

Shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) opened more than 50% up this morning after Biogen Inc (NASDAQ: BIIB) said it will buy the pharma co more_horizontal

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?

By InvestorPlace
July 28, 2023

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?

Reata Pharmaceuticals (NASDAQ: RETA ) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (NASDAQ: BIIB ). That de more_horizontal

Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?

By Zacks Investment Research
June 29, 2023

Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate more_horizontal

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

By Zacks Investment Research
June 19, 2023

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release. more_horizontal

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?

By Zacks Investment Research
June 9, 2023

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? more_horizontal

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

By Business Wire
June 6, 2023

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global more_horizontal

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

By Zacks Investment Research
May 11, 2023

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney more_horizontal


Search within

Pages Search Results: